SCHANGM

Does anybody have insight into the use of the partial remaining microcolumn of Gel IgG cards that have preiously gone through an incubation/centrifugation? Is this acceptable?

What methods do you use to store your unit segments?

What are your practices for providing phenotypically similar blood for patients with warm auto antibodies? Our transfusion service happily provides E and K negative units to warm auto patients lacking those antigens on the basis that there are easy to find but it is preferred not to attempt to locate antigen negative units to patients negative for c and e due to the lower frequency of available units. Is there information comparing the immunogenicity of the Rh antigens? I would like for the rationale behind our practices to be guided by not only likelihood of finding available units but also by preventing the warm auto patient from developing allo-antibodies as well.

Thanks- the positive DAT was found at extended crossmatch so it reasons to stand that we will not be able to transfuse this to anyone requiring extended crossmatch and had it been selected for a patient with electronic or IS crossmatch it would have been transfused. But now that we have identified this unit as having a positive DAT is further action necessary? Is there any reason to avoid issuing this unit?

Looking for feedback about transfusing DAT positive donor units. It seems like these red cells would have decreased cell survival, but I am having trouble locating anything that speaks to the subject. Anybody have info on this?

Looking for thoughts on completing ABIDs, specifically whether it is ideal to use selected cells from the original methodology. Our transfusion service currently uses solid phase as our primary method of testing as well as PeG. It seems of late that it is becoming increasing popular among staff to shotgun ABIDs and throw in Extend solid phase panels and PeG when faced with anything less than straightforward reaction patterns on an ID, rather than carefully selecting cells to complete rule outs. The end result is often confusing and makes it hard to review past work... It seems like there is a definate need for coaching here, but we are also looking at proposing reducing ordering of our panocells reagents not only to save money but with the possible added bonus of redirecting techs away from jumping straight to PeG unecessarily while maintaining it as an option for patients where it is truely needed. I would love to hear what other folks think about choosing the methodolgy for selected cells and ways to minimize throwing everything at an ABID.